Hantz Financial Services Inc. lowered its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 30.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 122,770 shares of the healthcare product maker’s stock after selling 52,786 shares during the period. Hantz Financial Services Inc.’s holdings in Abbott Laboratories were worth $12,135,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Bank of America Corp DE purchased a new position in Abbott Laboratories in the second quarter valued at approximately $1,603,607,000. Legal & General Group Plc bought a new position in Abbott Laboratories in the 2nd quarter worth about $1,082,524,000. Flossbach Von Storch SE bought a new stake in Abbott Laboratories during the 2nd quarter worth approximately $902,938,000. Jupiter Topco LLC purchased a new stake in Abbott Laboratories in the 2nd quarter worth approximately $732,788,000. Finally, BlackRock Inc. lifted its stake in Abbott Laboratories by 4.6% in the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after purchasing an additional 6,769,518 shares in the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other Abbott Laboratories news, EVP Mary Moreland sold 3,500 shares of the firm’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $116.00, for a total transaction of $406,000.00. Following the completion of the transaction, the executive vice president owned 100,791 shares of the company’s stock, valued at approximately $11,691,756. This trade represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.46% of the company’s stock.
Abbott Laboratories Stock Up 0.1%
Shares of NYSE:ABT opened at $108.59 on Monday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.45 and a quick ratio of 1.00. The company has a market cap of $188.08 billion, a PE ratio of 40.52, a P/E/G ratio of 1.90 and a beta of 0.54. The stock’s 50-day moving average is $103.93 and its 200 day moving average is $101.74. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $132.02.
Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, hitting analysts’ consensus estimates of $1.42. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. The company had revenue of $13.01 billion during the quarter, compared to analyst estimates of $12.99 billion. During the same quarter last year, the firm posted $1.30 earnings per share. The firm’s revenue was up 14.5% on a year-over-year basis. Sell-side analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year.
Abbott Laboratories Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $0.63 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is currently 94.03%.
Analyst Ratings Changes
Several research analysts have commented on ABT shares. JPMorgan Chase & Co. cut their price target on shares of Abbott Laboratories from $120.00 to $118.00 and set an “overweight” rating for the company in a report on Thursday, October 22nd. TD Cowen lowered their price objective on Abbott Laboratories from $135.00 to $118.00 and set a “buy” rating on the stock in a research report on Thursday, October 22nd. Robert W. Baird boosted their price objective on Abbott Laboratories from $121.00 to $123.00 and gave the stock an “outperform” rating in a report on Thursday, October 22nd. Rothschild & Co Redburn raised Abbott Laboratories from a “neutral” rating to a “buy” rating and increased their target price for the company from $119.00 to $127.00 in a research note on Friday, October 2nd. Finally, Wall Street Zen upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, October 24th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $118.32.
Get Our Latest Stock Analysis on Abbott Laboratories
About Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.
Read More
- Five stocks we like better than Abbott Laboratories
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
